TGFB1 and recessive dystrophic epidermolysis bullosa: Indeed, the angiotensin II type 1 receptor antagonist losartan counteracts the TGF-β signaling pathway, reduces ECM remodeling/fibrosis and ameliorates RDEB-associated cutaneous symptoms in mice [223].